Category: Startups

Bodywide immune response important for fighting cancer, Stanford researchers say

Fighting off cancer requires the concerted efforts of immune molecules throughout the body, rather than just in the tumor itself, according to a new study of laboratory mice by researchers at the Stanford University School of Medicine. The finding helps settle an ongoing dispute among clinicians as to whether systemic, or whole-body responses, are as important as a robust response by immune cells in the tumor itself.

Bodywide immune response important for fighting cancer, Stanford researchers say

Fighting off cancer requires the concerted efforts of immune molecules throughout the body, rather than just in the tumor itself, according to a new study of laboratory mice by researchers at the Stanford University School of Medicine. The finding helps settle an ongoing dispute among clinicians as to whether systemic, or whole-body responses, are as important as a robust response by immune cells in the tumor itself.

ObsEva Expands Leadership Team and Board of Directors with Industry Veterans

ObsEva SA , a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman’s reproductive health and pregnancy, announced today the appointment of a new Chief Financial Officer, Timothy M. Adams. Mr. Adams is located in Boston, Massachusetts, where the Company is currently hiring finance, IR and clinical operation people to support ObsEva’s clinical-stage programs in uterine fibroids, endometriosis, Assisted Reproductive Technology and preterm labor.

How Your Morning Coffee Might Slow Down Aging

To the age-old question – ” Is coffee bad for you ?” – researchers are in more agreement than ever that the answer is a resounding “no.” A new study published in the journal Nature Medicine found that older people with low levels of inflammation – which drives many, if not most, major diseases – had something surprising in common: they were all caffeine drinkers.

3 Little-Known Pharmaceutical Companies to Put on Your Radar

Over the past year, the best-performing drugmaker stocks all have had one thing in common: They received very little attention before providing patient investors windfall gains. Being considered insignificant in itself isn’t a great reason to scoop up shares of Teligent Brian Feroldi : Being called a “specialty generic” drug manufacturer might sound oxymoronic, but Teligent has stumbled on a clever business strategy that could make it a great stock to put on your watch list.

Deadline Upcoming in $4.5 Million Settlement in the Dynavax…

The Shareholders Foundation announced that a deadline is coming up on January 21, 2017 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Dynavax Technologies Corporation between April 26, 2012 and June 10, 2013. Investors who purchased a significant amount of shares of Dynavax Technologies Corporation between April 26, 2012 and June 10, 2013, have certain options and should contact the Shareholders Foundation by email at mail@shareholdersfoundation.com or call 858-779-1554.

Amy Schumer’s next stand-up special will premiere on Netflix

‘Very happy to be a part of the Netflix family for this special,’ the comic told per The Hollywood Reporter , before quipping: ‘Maybe now they will look at my Stranger Things audition tape to play the demogorgon for Season 2.’ Her Comedy Central sketch show Inside Amy Schumer is currently on hiatus ‘for the foreseeable future,’ as she’s written on Twitter , though the network’s renewed it. The set she’s had filmed for the upcoming special took place at the Bellco Theatre in the Colorado Convention Centre in Denver early last November.

Fosun Pharma unveils plan to battle cancer with early diagnosis and cost-effective treatment options

Fosun Pharmaceutical, a leading healthcare group on the mainland, plans to focus on early diagnosis and cost-effective treatment of cancer by using the world’s latest technologies such as robotic-assisted medical devices. Chen Qiyu, chairman of Shanghai-based Fosun Pharma, a subsidiary of the mainland’s largest non-state-owned investment conglomerate Fosun Group, said the company would introduce advanced technologies available in the United States to the Chinese market.

Intuity Medical Increases Series 3 Funding to $55M With an Additional Close of $15M

The additional financing will help fund the infrastructure build and commercial launch of Intuity Medical’s POGO AutomaticTM Blood Glucose Monitoring System, the first fully-integrated blood glucose monitor SUNNYVALE, Calif., January 5, 2017– Intuity Medical, Inc., a privately-held company developing innovative technologies for diabetes management, announced today that it has closed an additional $15 million, which brings the total Series 3 equity financing for the company to $55 million.

Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year

Despite a generally bleak year for Gilead, and for biotech stocks in general, shares of Exelixis, Inc. Can these biotechs continue climbing throughout the new year and beyond, or are they about to sputter and run out of fuel? Let’s look at what’s propelling them upward to see why they might be better picks than Gilead Sciences. A string of good news for Exelixis’ lead cancer drug made this one of the best-performing biotech stocks of 2016.

Doug Ford: Following the historical line of the chemical industry

Two years ago in my last column for the year, I wrote about Tu YouYou, the Chinese woman scientist who was until 2011 unknown even in China for her work that saved many millions of lives after she found an effective treatment for malaria. I found her story particularly interesting because of a coincidental connection with my late wife, Oralie.

Exelixis Inc. (EXEL) Stake Raised by Swiss National Bank

Swiss National Bank increased its position in shares of Exelixis Inc. by 1.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 367,300 shares of the biotechnology company’s stock after buying an additional 5,600 shares during the period.

Biotech Poised for Rebound

… election of Donald Trump has buoyed the prospects of financials, energy and industrials. After an initial surge, health-care and biotech have not benefited nearly as much as other industries but definitely not as badly as utilities or consumer …

Top Insider Buys of the Week

… share. The price of the stock has decreased by 0.13% since. Abbott Laboratories is an American-based international health care company. It has more than 74,000 employees in 150 countries. Some products include pharmaceutical drugs, medical devices …

Portola Pharmaceuticals Announces FDA Accepts New Drug Application…

Portola Pharmaceuticals, Inc.A today announced that the U.S. Food and Drug Administration accepted Portola’s New Drug Application granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to six months from the standard review period of 10 months.

SP Scientific webinar shows improvements in lyophilization through ControLyoa Technology

SP Scientific announces the on-demand availability of a popular webinar** by Jake Luoma of Genentech Inc. that discusses how controlled nucleation has emerged as a technology which promises improvements in lyophilization process throughput and consistency. In this presentation, Mr. Luoma examines the benefits of the technology for high fill-volume configurations and presents new data regarding the mechanism of the ControLyo Technology.

Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424

Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that it has entered into a collaboration with the National Cancer Institute , part of the National Institutes of Health , to study TH-3424, the company’s new drug candidate for the treatment of cancer. The collaboration will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia xenograft cell lines with high AKR1C3 expression.

View Press Release

A Once-Daily Treatment that Demonstrated Comparable Efficacy with Improved Renal and Bone Laboratory Safety Parameters Compared to Tenofovir Disoproxil Fumarate — )–Gilead Sciences, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved Vemlidy 25mg, a once-daily treatment for suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function. Vemlidy is a novel targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of tenofovir disoproxil fumarate 300mg.

The benefits of meditation – or mindfulness – for investors

The late co-founder and CEO of Apple, Inc., Steve Jobs was a long-time practitioner of meditation and attributed much of his career success to mindfulness’s ability to boost perception and intuition in creatives. The late co-founder and CEO of Apple, Inc., Steve Jobs was a long-time practitioner of meditation and attributed much of his career success to mindfulness’s ability to boost perception and intuition in creatives.